Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FP008 in Advanced Solid Tumors
NCT06990698Phase 1Recruiting
- Sponsor
- Fapon Biopharma
- Start
- Jun 2025
- Primary completion
- May 2028
- Modality
- Immunomodulatory ADCs, Engineered Antibody Formats, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of FP008 in solid tumor, sponsored by Fapon Biopharma. Primary endpoints: Dose-limiting toxicities up to 2 years, Severity of Treatment-Emergent Adverse Events leading to discontinuation up to 2 years and 5 more. Started Jun 2025; status: recruiting.
02
Drugs
FP008
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT06990698.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06990698.